A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers

Diabet Med. 2004 Jul;21(7):786-9. doi: 10.1111/j.1464-5491.2004.01166.x.


Aims: To evaluate the use of a new cell-tailored carrier surface (TranCell) for delivery of autologous keratinocytes to promote wound healing in patients with chronic neuropathic foot ulcers.

Methods: TranCell is a sterile medical grade polymer coated with a plasma-polymerized functional surface containing 20% carboxylic acid which enables keratinocytes to attach and proliferate. Six diabetic patients with neuropathic ulcers resistant to conventional therapy were treated with weekly applications of autologous keratinocytes delivered on TranCell. A split-thickness skin biopsy was taken from each patient followed by isolation, expansion and freezing down of keratinocytes. Keratinocytes were thawed and seeded on TranCell 48 h prior to application. This procedure was repeated weekly in addition to conventional therapy until wound healing was achieved.

Results: Complete healing was achieved in six out of nine ulcers in six patients, a reduction in ulcer size was achieved in one ulcer and no response was seen in one ulcer. Treatment was discontinued in one patient due to development of Methicillin-Resistant Staphylococcus aureus (MRSA) after only three applications of TranCell. Wound healing took 6-17 applications over 6-20 weeks. There were no recurrences in the healed ulcers after a follow-up of 6 months.

Conclusions: TranCell delivery of autologous cells is a promising treatment for chronic diabetic foot ulcers with no side-effects and no recurrence in the healed ulcers.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Bandages*
  • Chronic Disease
  • Diabetic Foot / pathology
  • Diabetic Foot / therapy*
  • Humans
  • Keratinocytes / transplantation*
  • Middle Aged
  • Skin, Artificial*
  • Treatment Outcome
  • Wound Healing